Proton Pump Inhibitors Market Size, Share, and Trends 2025 to 2034

The global proton pump inhibitors (PPIs) market size is calculated at USD 4.29 billion in 2025 and is forecasted to reach around USD 6.98 billion by 2034, accelerating at a CAGR of 5.56% from 2025 to 2034. The North America market size surpassed USD 1.62 billion in 2024 and is expanding at a CAGR of 5.59% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : July 2025  |  Report Code : 6317  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Proton Pump Inhibitors (PPIs) Market 

5.1. COVID-19 Landscape: Proton Pump Inhibitors (PPIs) Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Proton Pump Inhibitors (PPIs) Market, By Drug Type

8.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Drug Type

8.1.1. Esomeprazole

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Omeprazole

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Dexlansoprazole

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Pantoprazole

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Others

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Proton Pump Inhibitors (PPIs) Market, By Route of Administration

9.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Route of Administration

9.1.1. Oral

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Injectable

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Proton Pump Inhibitors (PPIs) Market, By Indication

10.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Indication

10.1.1. Gastroesophageal Reflux Disease

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Heartburn

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Peptic Ulcers

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Proton Pump Inhibitors (PPIs) Market, By Distribution Channel 

11.1. Proton Pump Inhibitors (PPIs) Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Drug Stores

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Proton Pump Inhibitors (PPIs) Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Type

12.1.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.3. Market Revenue and Volume Forecast, by Indication

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Type

12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.5.3. Market Revenue and Volume Forecast, by Indication

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Type

12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.1.6.3. Market Revenue and Volume Forecast, by Indication

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Type

12.2.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.3. Market Revenue and Volume Forecast, by Indication

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Type

12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.5.3. Market Revenue and Volume Forecast, by Indication

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Type

12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.6.3. Market Revenue and Volume Forecast, by Indication

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Type

12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.7.3. Market Revenue and Volume Forecast, by Indication

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Type

12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.2.8.3. Market Revenue and Volume Forecast, by Indication

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Type

12.3.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.3. Market Revenue and Volume Forecast, by Indication

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Type

12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.5.3. Market Revenue and Volume Forecast, by Indication

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Type

12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.6.3. Market Revenue and Volume Forecast, by Indication

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Type

12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.7.3. Market Revenue and Volume Forecast, by Indication

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Type

12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.3.8.3. Market Revenue and Volume Forecast, by Indication

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Type

12.4.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.3. Market Revenue and Volume Forecast, by Indication

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Type

12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.5.3. Market Revenue and Volume Forecast, by Indication

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Type

12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.6.3. Market Revenue and Volume Forecast, by Indication

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Type

12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.7.3. Market Revenue and Volume Forecast, by Indication

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Type

12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration

12.4.8.3. Market Revenue and Volume Forecast, by Indication

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Type

12.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.3. Market Revenue and Volume Forecast, by Indication

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Type

12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.5.3. Market Revenue and Volume Forecast, by Indication

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Type

12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration

12.5.6.3. Market Revenue and Volume Forecast, by Indication

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. AstraZeneca

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bayer AG

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Cadila Pharmaceuticals

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Eisai Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GlaxoSmithKline PLC

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Takeda Pharmaceuticals

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Sanofi SA

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Dr. Reddy’s Laboratories

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Redhill Pharma Limited

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Cipla Limited

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global proton pump inhibitors (PPIs) market is expected to increase from USD 4.06 billion in 2024 to USD 6.98 billion by 2034.

The proton pump inhibitors (PPIs) market is expected to grow at a compound annual growth rate (CAGR) of around 5.56% from 2025 to 2034.

The major players in the proton pump inhibitors (PPIs) market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eisai Inc., GlaxoSmithKline PLC, Pfizer Inc., Takeda Pharmaceuticals, Sanofi SA, Dr. Reddy’s Laboratories, Redhill Pharma Limited, and Cipla Limited.

The driving factors of the proton pump inhibitors (PPIs) market are the growing awareness of gastrointestinal disorders and improved diagnostic capabilities are leading to more diagnoses and treatment with PPIs, which is contributing to market growth. 

North America region will lead the global proton pump inhibitors (PPIs) market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client